Publication | Closed Access
Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration
32
Citations
20
References
2013
Year
5 mg/mL pazopanib eye drops resulted in mean improvement in BCVA at Day 29 and improvements in vision. However, improvement in macular oedema for age-related macular degeneration was found only in the subset of subjects with the CFH Y402H TT genotype, warranting further investigation.
| Year | Citations | |
|---|---|---|
Page 1
Page 1